neoag
Neoantigen × AI
Daily research signal
№51Brief2026-10-16

NeoVax plus nivolumab feasible in platinum-sensitive ovarian cancer

Today's pair connects a clinical feasibility readout with the mechanistic tooling behind it: a phase 1 NeoVax-plus-nivolumab study in platinum-sensitive ovarian cancer clears safety and feasibility bars in a tumor type where personalized vaccines have been hard to execute, while an osteosarcoma case report shows post-vaccination TCR discovery is now practical at single-cell resolution.bioRxiv

Both also expose operational realities investors should price in — biopsy tissue adequacy was the leading reason patients never reached dosing, and vaccine-elicited TCRs can turn out MHC class-II restricted, complicating direct TCR-T translation.bioRxiv

2new stories
ClinicalyesterdayNew

Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer - CancerNetwork

Phase 1 NeoVax trial (NCT04024878, published in Nature Medicine) of a personalized neoantigen vaccine followed by nivolumab in platinum-sensitive high-grade epithelial ovarian cancer met its feasibility endpoint with no unexpected safety signals; 9 of 10 vaccinated patients completed all planned doses. Enrollment funnel matters for manufacturing economics: of 22 patients prescreened between November 2020 and September 2023, only 12 consented to treatment and 10 were vaccinated, with inadequate core-needle biopsy tissue the top attrition cause (n=4). Vaccination rates diverged sharply by setting — 75% of evaluable first-recurrence patients (Cohort B) versus 11% of newly diagnosed patients (Cohort A) — suggesting recurrence is the more executable indication. Common vaccine-associated AEs were injection site reactions, myalgia, chills, and neutropenia (50–70% each), with two grade 3 events reported.

Ovarian cancer
news · yesterday · CancerNetwork

Also new today01

01
ClinicalyesterdayNew

Discovery of frameshift-associated TCRs following personalized neoantigen vaccination in a patient with osteosarcoma

A case report in locally recurrent osteosarcoma demonstrates an end-to-end immune monitoring workflow after personalized neoantigen vaccination: in vitro peptide stimulation plus IFN-gamma ELISPOT detected post-vaccination responses to 12 of 15 tested peptides, and 10x single-cell TCR sequencing yielded 26 candidate TCRs, of which 25 generated functional TCR-T cells. Only 4 were specific to vaccine peptides, and all 4 proved MHC class-II restricted — a key constraint for anyone planning to spin vaccine-discovered TCRs into conventional (class I-targeted) TCR-T assets. For the field, this validates single-cell TCR discovery as a pharmacodynamic readout of whether a vaccine actually elicited trackable antigen-specific clones, not just bulk ELISPOT signal.

Peptide vaccinesTCR & T-cell receptor
biorxiv · yesterday · Bennett, S. N.; Alley, J.; Shabrang, M.; Garness, J.; McKinnon, K.; Smith, A.; Inabinett,

Explore the field

TopicsTrialsLearn